Exhibit 99.1

ImmuCell

イミュセル社、2012年12月期決算発表

2025年6月30日に終了した四半期

For Immediate Release

メイン州ポートランド-2025年8月14日-イミュセル・コーポレーション（Nasdaq: ICCC）（以下「イミュセル」または「当社」）は本日、乳牛・肉牛の健康と生産性を向上させる科学的に実証された実用的な製品を開発・製造・販売する成長中の動物用医薬品企業として、2025年6月30日に終了した四半期決算（未監査）を発表した。

Product Sales Highlights:

2025年第2四半期の予備的な未監査の製品売上高は、2025年7月9日に初めて報告された。これらの数値に変更はない。

Management’s Discussion:

「イミュセルのマイケル・F・ブリガム社長兼最高経営責任者（CEO）は、「2025年6月30日をもって、受注残を事実上解消することができました。「一般的に売上が減少する第3四半期を迎えるにあたり、販売代理店が保有したい在庫を再充填しました。現在、年末から2026年第1四半期にかけての販売最盛期に向けて、顧客の需要に応えるための在庫を確保しています。

「イミュセルのティモシー・C・フィオリ最高財務責任者（CFO）は、「2025年6月30日に終了した3カ月間と6カ月間の売上総利益率は、それぞれ44%と43%に改善しました。「この売上総利益率の改善により、2025年6月30日に終了した3ヶ月間と6ヶ月間は、それぞれ約50万2千ドルと190万ドルの純利益を計上することができました。

「Re-Tain®に関しては、2025年後半から2026年第1四半期にかけて、現場での製品性能に関する市場からのフィードバックを収集するため、治験薬使用を開始しました。「同時に、製品開発費を削減し、製品機会に関する戦略的選択肢の可能性を探っています。

Certain Other Financial Results:

2025年6月30日現在の貸借対照表データ:

将来の見通しに関する記述についての注意事項（セーフハーバー・ステートメント）:

This Press Release and the statements to be made in the related conference call referenced herein contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals and pending or anticipated regulatory inspections of our facilities and those of our contract manufacturers; future demand for our products; future adoption of Re-Tain® by dairy producers; growth in acceptance of our First Defense® product line by dairy and beef producers; the impact of international disputes (including Russia’s invasion of Ukraine and unrest in the Middle East) on the world economy including inflation and the price and availability of grain and oil; the impact of the global supply-chain disruptions on our ability to obtain, in a timely and cost-effective fashion, all the supplies and components we need to produce our products; the impact of inflation, tariffs and rising interest rates on our operating expenses and financial results; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts; future incidence rates of subclinical mastitis and producers’ level of interest in treating subclinical mastitis; the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated by current products and products still in development; our ability to increase production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships; the efficacy of our contamination remediation efforts; whether or not we will experience future contamination events; the anticipated costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects; the robustness of our manufacturing processes to meet future demand and related technical issues; estimates about our future production capacity, efficiency and yield; the salability of products currently held in inventory pending regulatory approval; future regulatory requirements relating to our products; future expense ratios and margins; the future consequences and effectiveness of our investments in our business; future compliance with, or waivers of, bank debt covenants; anticipated changes in our manufacturing capabilities and efficiencies; our future effectiveness in competing against competitors within both our existing and our anticipated product markets; projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements are intended to provide management’s current expectation of future events as of the date of this earnings release, are based on management’s estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the First Defense® product line and Re-Tain®), competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the SEC, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

5 of 5